Vera Therapeutics, Inc. (VERA) NASDAQ
31.26
-2.68(-7.90%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
31.26
-2.68(-7.90%)
Currency In USD
| Previous Close | 33.94 |
| Open | 33.99 |
| Day High | 35.21 |
| Day Low | 31.03 |
| 52-Week High | 56.05 |
| 52-Week Low | 19.07 |
| Volume | 1.7M |
| Average Volume | 1.19M |
| Market Cap | 2.24B |
| PE | -5.64 |
| EPS | -5.54 |
| Moving Average 50 Days | 38.1 |
| Moving Average 200 Days | 36.51 |
| Change | -2.68 |
Vera Therapeutics Appoints Christopher Hite to Board of Directors
GlobeNewswire Inc.
Mar 05, 2026 2:00 PM GMT
BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announc
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
GlobeNewswire Inc.
Jan 28, 2026 12:30 PM GMT
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 12:30 PM GMT
BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic